Structural changes in the SARS-CoV-2 spike E406W mutant escaping a clinical monoclonal antibody cocktail

Amin Addetia^{1,2}, Young-Jun Park^{2,3}, Tyler Starr^{3,4}, Allison J. Greaney³, Kaitlin R Sprouse², John E. Bowen², Sasha W. Tiles⁵, Wesley C. Van Voorhis⁵, Jesse D. Bloom^{3,4}, Davide Corti⁶, Alexandra C. Walls^{2,3}, David Veessler^{2,3*}

¹Molecular and Cellular Biology Graduate Program, University of Washington, Seattle, Washington, USA

²Department of Biochemistry, University of Washington, Seattle, Washington, USA

³Howard Hughes Medical Institute, Seattle, WA 98195, USA

⁴Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA

⁵Center for Emerging and Re-emerging Infectious Diseases, Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA

⁶Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.

*Correspondence: dveessler@uw.edu

The SARS-CoV-2 receptor-binding domain (RBD) E406W mutation abrogates neutralization mediated by the REGEN-CoV therapeutic monoclonal antibody (mAb) COVID-19 cocktail and the cilgavimab (AZD1061) mAb. Here, we show that this residue substitution remodels the ACE2-binding site allosterically, thereby dampening receptor recognition severely and altering the epitopes recognized by these three mAbs. Although vaccine-elicited neutralizing antibody titers are decreased similarly against the E406 mutant and the Delta or Epsilon variants, broadly neutralizing sarbecovirus mAbs, including a clinical mAb, inhibit the E406W spike mutant.

Main

The receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein is responsible for interacting with the host receptor ACE2 and initiating viral entry into cells¹⁻³. The SARS-CoV-2 RBD is the target of the majority of neutralizing antibodies elicited by SARS-CoV-2 infection and COVID-19 vaccination as well as monoclonal antibodies (mAbs) used therapeutically⁴⁻⁸. Binding and neutralization of SARS-CoV-2 by individual mAbs can be escaped by single RBD residue mutations, which led to the development of therapeutic cocktails comprising two mAbs recognizing non-overlapping epitopes⁹⁻¹². These cocktails have a higher barrier for the emergence of neutralization escape mutants than the individual

constituting mAbs, as typically at least two distinct amino-acid substitutions are required to evade neutralization by a two-mAb cocktail.

The REGEN-COV cocktail consists of two mAbs, casirivimab (REGN10933) and imdevimab (REGN10987) that bind non-overlapping RBD epitopes in the receptor-binding motif (RBM), and block ACE2 attachment^{11,12}. We previously mapped all possible RBD residue mutations that permit escape from the REGEN-COV mAb cocktail and the cilgavimab (AZD1061) mAb which led us to identify that the E406W substitution abrogated binding and neutralization of both REGEN-COV mAbs and the cocktail⁹ as well as binding of cilgavimab¹³. Unexpectedly, residue E406 is located outside of the epitopes recognized by casirivimab, imdevimab and cilgavimab, suggesting this mutation might influence the overall structure of the RBD (presumably through an allosteric effect) while retaining detectable binding to dimeric human ACE2⁹.

To understand the molecular basis of the E406W-mediated escape from the REGEN-COV cocktail and cilgavimab, we characterized the SARS-CoV-2 spike ectodomain trimer structure harboring the E406W mutation using single-particle cryo-electron microscopy. 3D classification of the dataset revealed the presence of two conformational states: one with three RBDs closed and one with one RBD open accounting for approximately 70% and 30% of particles, respectively. We determined a structure of the closed S state at 2.3 Å resolution applying C3 symmetry (**Figure 1, Figure S1 and Table 1**). Symmetry expansion, focused classification and local refinement yielded an RBD reconstruction at 3.4 Å resolution which was used for model building and analysis (**Figure 1, Figure S1 and Table 1**).

The E406W substitution places the introduced side chain indol ring in a position sterically incompatible with the neighboring Y495 phenol side chain, inducing a rotameric rearrangement of the latter residue relative to the ACE2-bound RBD structure¹⁴ or apo S ectodomain trimer structures^{1,15}. This results in major conformational reorganization of residues 443-450 and 495-503 which experience up to 4.5 Å shift relative to previously determined structures^{1,15}. Although the organization of residues 475-484 are only subtly different in the E406W RBD relative to apo S structures^{1,15}, it deviates markedly more from the ACE2-bound RBD structure¹⁴ or the REGEN-COV-bound RBD structure¹¹ (**Figure 1a**). Imdevimab (REGN10987) recognizes an epitope residing at the interface between antigenic sites Ia and IIa⁵ and forms extensive interactions with residues 440-449 that would sterically clash with the mAb heavy chain in the E406W RBD structure (**Figure 1b**). Casirivimab (REGN10933) interacts with residues 417, 453-456 and 475-490 (within antigenic site Ia⁵) and the distinct conformation of the latter residues in the REGEN-COV-bound RBD and E406W apo S structures likely precludes mAb binding through steric clash with the mAb light chain (**Figure 1c**). Our data therefore shows that the E406W mutation disrupts the antigenic sites recognized by casirivimab (REGN10933) and imdevimab (REGN10987) allosterically, which are positioned 5 and 20 Å away, respectively⁹. Similar to imdevimab, the loss of cilgavimab (AZD1061) binding to the E406W RBD¹³ is explained by the

structural reorganization of residues 443-450 which are recognized by this mAb (**Figure S2**).

These RBD conformational changes also alter the ACE2-interacting surface resulting in the predicted loss of several hydrogen bonds formed between the ACE2 D38 and SARS-CoV-2 Y449 side chains as well as the ACE2 Q42 side chain and the SARS-CoV-2 Y449 side chain and G446 main chain carbonyl (**Figure 1d**). Accordingly, we observed that the monomeric human ACE2 ectodomain bound with a 14-fold reduced affinity to immobilized SARS-CoV-2 E406W RBD ($K_D=1.34\ \mu\text{M}$) relative to wildtype (Wuhan-Hu-1) RBD ($K_D=93.9\ \text{nM}$) using biolayer interferometry (**Figure S3a-c and Table S2**). This reduction of ACE2 binding affinity is expected to dampen viral fitness severely, as previously observed for another point mutation decreasing ACE2 binding¹⁶ (**Figure S3d**).

Figure 1. The E406W mutation remodels the SARS-CoV-2 RBD allosterically. **a**, Structural superimposition of the Wuhan-Hu-1 RBD (E406, gold, PDB 6m0j, ACE2 not displayed) and the W406 RBD (light blue). **b-c**, Structural superimposition of the imdevimab/casirivimab-bound Wuhan-Hu-1 RBD (E406, gold, PDB 6xdj) and the W406 RBD (light blue). Steric clashes indicated with red stars. **d**, Structural superimposition of the ACE2-bound Wuhan-Hu-1 RBD (E406, gold, PDB 6m0j) and the W406 RBD (light blue). Hydrogen bonds shown as dotted lines.

A few broadly neutralizing sarbecovirus human mAbs have been recently described and shown to be resilient to the observed SARS-CoV-2 antigenic drift, to recognize distinct RBD antigenic sites, and protect small animals against challenge with SARS-CoV-2 variants of concern or other sarbecoviruses^{10,16,18–22}. To evaluate the influence of the aforementioned structural changes on neutralization by these mAbs, we compared the concentration-dependent inhibition of S309, S2E12 and S2X259 against VSV particles pseudotyped with the G614 spike or the W406/G614 spike. Each of these three mAbs neutralized with comparable potency the G614 and W406/G614 pseudoviruses (**Table S3**), indicating they retain activity against this mutant (**Figure 2A and Figure S4**). As predicted based on structural data^{5,10}, the S2H14 mAb failed to neutralize the spike W406/G614 pseudovirus due to the reorganization of the RBM (**Figure 2A and Figure S4**). Moreover, these data are consistent with the fact that binding to the SARS-CoV-2 W406 RBD was unaffected for S2E12 and abrogated for S2H14¹⁰.

Finally, we set out to assess the impact of the E406W mutation on vaccine-elicited plasma neutralizing activity using samples obtained from individuals who had received 2 doses of either Pfizer BNT162b2 or Moderna mRNA-1273 COVID-19 vaccine (**Table S4**). We observed 2.5-fold (BNT162b2, range: 1.2–4.6) and 2.4-fold (mRNA-1273, range: 1.5–3.8) reduction in neutralization potencies against the W406/G614 spike pseudovirus compared to G614 spike-harboring pseudovirus (**Figure 2B-C and Figure S5**). These data indicate that the single E406W mutation leads to moderate erosion of vaccine-elicited polyclonal neutralizing antibodies, comparable to the SARS-CoV-2 Epsilon variant²³ or the Delta variant²⁴.

Figure 2. Evaluation of the neutralizing activity of several sarbecovirus broadly neutralizing mAbs and vaccine-elicited polyclonal antibodies. **a**) Neutralization

potency (50% inhibition concentration, IC₅₀) of the monoclonal antibodies S309, S2E12, S2X259, and S2H14 against VSV pseudotyped with either the wildtype (G614) or the E406W mutant spike protein. Non-neutralizing values are shown as 2×10^4 ng/mL, the limit of detection of the assay, as indicated by a dotted line. **b-c)** Neutralization potency (50% inhibition dilution, ID₅₀) of sera collected from individuals vaccinated with either Pfizer Cominarty (b) or Moderna's mRNA-1273 (c) against VSV pseudotyped with SARS-CoV-2 wildtype (G614) or E406W spike. ID₅₀ values measured against the two pseudoviruses for each sample are connected by a line. The dotted line indicates the limit of detection of the assay.

The ongoing SARS-CoV-2 genetic drift yielded variants harboring numerous mutations, some of them altering transmissibility, immune evasion, replication kinetics or disease severity relative to the ancestral SARS-CoV-2 isolate^{7,23,25–307,23,25,30–37}. Although the E406W mutation promotes escape from REGEN-COV- and cilgavimab (AZD1061)-mediated neutralization, it requires multiple nucleotide substitutions from the Wuhan-Hu-1 spike sequence, has a strong deleterious effect on ACE2 binding and has not been detected in clinical isolates to date. Several best-in-class broadly neutralizing sarbecovirus mAbs are unaffected by the E406W mutation and COVID-19 mRNA vaccine-elicited polyclonal antibodies retain a substantial fraction of their activity against this mutant, indicating several strategies are available should a E406W mutant virus emerge in the future. Finally, our data showcase the structural and functional plasticity of the SARS-CoV-2 RBD¹⁷ that evolves under selective pressure from the host immune responses and the necessity to retain viral fitness of progeny viruses.

Acknowledgements

We thank Hideki Tani (University of Toyama) for providing the reagents necessary for preparing VSV pseudotyped viruses. This study was supported by the National Institute of Allergy and Infectious Diseases (DP1AI158186 and HHSN272201700059C to DV, and R01AI141707 to JDB), the National Institute of General Medical Sciences (R01GM120553 to DV), the National Institute of Health Cellular and Molecular Biology Training Grant (T32GM007270 to A.A.), a Pew Biomedical Scholars Award (DV), an Investigators in the Pathogenesis of Infectious Disease Awards from the Burroughs Wellcome Fund (DV and JDB), Fast Grants (DV), the Bill & Melinda Gates Foundation (OPP1156262 to DV and INV-004949 to JDB), the University of Washington Arnold and Mabel Beckman cryoEM center and the National Institute of Health grant S10OD032290 (to D.V.) and grant U01 AI151698 for the United World Antiviral Research Network (UWARN) as part of the Centers for Research in Emerging Infectious Diseases (CREID) Network. TNS is an Howard Hughes Medical Institute Fellow of the Damon Runyon Cancer Research Foundation. JDB and DV are investigators of the Howard Hughes Medical Institute.

Author contributions

Conceptualization: AA, T.N.S., A.J.G., J.B., A.C.W. and DV. Pseudovirus entry assays: AA and ACW. BLI measurements: AA. Provided unique reagents: D.C., SWT, WCVV Data analysis: AA and DV. Supervision: DV. Writing – original draft: AA and DV. Writing – review and editing: all authors

Competing interests

The Veessler laboratory has received a sponsored research agreement from Vir Biotechnology Inc. J.D.B. consults for Moderna and Flagship Labs 77 on topics related to viral evolution, and is an inventor on Fred Hutch licensed patents related to viral deep mutational scanning. DC is an employee of Vir Biotechnology Inc. and may hold shares in Vir Biotechnology Inc.

Additional Information

Correspondence and requests for materials should be addressed to David Veessler (dveessler@uw.edu).

Methods

Cell culture

Expi293 cells were grown in Expi293 media at 37°C and 8% CO₂ rotating at 130 RPM. HEK-293T cells and HEK-293T cells stably expressing the human ACE2 receptor (HEK-ACE2)³⁸ were grown in DMEM supplemented with 10% FBS and 1% PenStrep at 37°C and 5% CO₂. Vero cells stably expressing the human protease TMPRSS2 (Vero-TMPRSS2) were grown in DMEM supplemented with 10% FBS, 1% PenStrep, and 8 µg/mL puromycin at 37°C and 5% CO₂.

Constructs

The construct encoding spike ectodomain harboring the E406W mutation was obtained from the Institute for Protein Design. The spike ectodomain was codon optimized, stabilized with the hexapro mutations³⁹ and mutation of the furin cleavage site (₆₈₂RRAR₆₈₅ to ₆₈₂GSAS₆₈₅), and inserted into the pCDNA3.1 vector containing a C-terminal foldon followed by an avi tag and an octa-histidine tag.

The construct encoding the E406W RBD was generated by performing around-the-horn mutagenesis using a pCMVR vector encoding the wildtype SARS-CoV-2 RBD containing an N-terminal mu-phosphatase signal peptide and a C-terminal avi tag and octa-histidine tag. The boundaries for the SARS-CoV-2 RBD in this construct were ₃₂₈RFPN₃₃₁ to ₅₂₈KKST₅₃₁.

Recombinant protein expression and purification

To produce the SARS-CoV-2 spike ectodomain containing the E406W mutation, 125 mL of Expi293 cells were grown to density of 2.5×10^6 cells per mL and transfected with 125 μ g of DNA using PEI MAX diluted in Opti-MEM. The cells were grown for four days after which the supernatant was clarified by centrifugation. The recombinant ectodomain was purified using a nickel HisTrap FF affinity column, washed with 10 column volumes of 20 mM imidazole, 25 mM sodium phosphate pH 8.0, and 300 mM NaCl, and eluted with a 500 mM imidazole gradient. The purified proteins were buffer exchanged and concentrated in 20 mM sodium phosphate pH 8 and 100 mM NaCl using a 100 kDa centrifugal filter. The proteins were flash frozen and stored at -80°C until use.

The wildtype, B.1.1.7, and E406W RBDs were produced by transfecting 25 mL of Expi293 cells at a density of 2.5×10^6 cells per mL with 25 μ g of DNA using the ExpiFectamine 293 Transfection Kit. The cells were grown for four days and the resulting supernatant was collected and clarified by centrifugation. The recombinant RBD was purified using a nickel HisTrap HP affinity column, washed with 10 column volumes of 20 mM imidazole, 25 mM sodium phosphate pH 8.0, and 300 mM NaCl, and eluted using a 500 mM imidazole gradient. The resulting protein was buffer exchanged and concentrated using a 10 kDa centrifugal filter. Next, the purified RBDs were biotinylated using the BirA biotin-protein ligase reaction kit (Avidity). The biotinylated proteins were re-purified and concentrated as described above. The proteins were flash frozen and stored at -80°C until use.

Cryo-EM sample preparation and data collection

Purified SARS-CoV-2 spike ectodomain harboring the E406W mutation was added to a freshly glow discharged 2.0/2.0 UltraFoil grid (200 mesh). The grid was then plunge frozen using a Vitrobot MarkIV (ThermoFisher) with a blotting force of 0 and time of 6.5 seconds at 100% humidity and 23°C . Data were acquired on a FEI Titan Krios transmission electron microscope operated at 300 kV and equipped with a Gatan K3 direct detector and Gatan Quantum GIF energy filter. Automated data acquisition was carried out using Leginon⁴⁰. The dose rate was adjusted to 15 counts/pixel/s and each movie was acquired in 75 frames of 40 ms with pixel size of 0.843 Å and a defocus range comprised between 0 and $-2.6 \mu\text{m}$.

CryoEM data processing

Movie frame alignment, estimation of the microscope CTF, particle picking, and extraction (with a downsampled pixel size of 1.686 Å and box size of 260 pixels²) were completed using WARP⁴¹. Reference-free 2D classification was performed using cryoSPARC to select for well-defined particle images⁴². These selected particles were then used for 3D classification with 50 iterations (angular sampling 7.5° for 25 iterations followed by 1.8° with local search for 25 iterations) using Relion and a previously reported closed model for the SARS-CoV-2 spike ectodomain (PDB: 6VXX) as the initial model without imposing any symmetry. 3D refinements were carried out using non-uniform refinement along with per-particle defocus refinement in cryoSPARC⁴³ after

which particles images were subjected to Bayesian polishing using Relion⁴⁴ and re-extracted with a box size of 512 pixels and a pixel size of 1 Å. Another round of non-uniform refinement followed by per-particle defocus refinement followed by another non-uniform refinement was conducted in cryoSPARC. Next, 86 optics groups were defined based on the beamtilt angle used for data collection and another round of non-uniform refinement with global and per-particle defocus refinement concurrently was conducted in cryoSPARC. To better resolve the RBD, focus 3D classification was carried out using symmetry expanded particles and a mask over residues 440-452 and 495-505 of the RBD using a tau factor of 200 in Relion^{45,46}. Particles from the classes with the best resolved local density were selected and then subjected to local refinement using cryoSPARC. Reported resolutions are based on the gold-standard Fourier shell correlation of 0.143 criterion and Fourier shell correlation curves were corrected for the effects of soft masking by high-resolution noise substitution^{47,48}.

Model building and refinement

USCF Chimera⁴⁹ and Coot⁵⁰ were used to fit atomic models of the SARS-CoV-2 RBD and ectodomain (PBD: 6M0J, 7LXY). Models were refined and rebuilt into the map using Coot⁵⁰ and Rosetta^{51,52}.

Biolayer interferometry

Biotinylated wildtype, B.1.1.7, or E406W RBD at a concentration of 5 ng/μL in 10X kinetics buffer was loaded at 30C onto pre-hydrated streptavidin biosensor to a 1 nm total shift. The loaded tips were then dipped into a 1:3 dilution series of monomeric hACE2 beginning at 900 nM, 300 nM, or 7,500 nM for 300 seconds followed by dissociation in 10X kinetics buffer for 300 seconds. The resulting data were baseline subtracted and curves were fitted using Octet Data Analysis HT software v12.0 and plotted in GraphPad Prism 9.

Pseudotyped VSV production

E406W and wildtype pseudotyped VSV particles were produced as previously described^{23,24}. Briefly, 5 x 10⁶ HEK-293T cells were seeded in 10 cm² poly-D-lysine coated plates and grown overnight until they reached ~70% confluency. The cells were then washed 5 times with Opti-MEM (Life Technologies) and transfected with 24 μg of plasmid encoding either the wildtype or E406W SARS-CoV-2 spike protein using Lipofectamine 2000 (Life Technologies). Four hours at transfection, an equal volume of DMEM supplemented with 20% FBS and 2% PenStrep was added to the cells. Twenty to 24 hours following transfection, the cells were washed 5 times with DMEM and infected with VSVΔG/Fluc. Two hours after infection, the cells were washed 5 times with DMEM and grown in DMEM supplemented with 10% FBS and 1% PenStrep along with an anti-VSV-G antibody (I1-mouse hybridoma supernatant diluted 1:25, from CRL-2700, ATCC). Twenty to 24 hours later, the supernatant was collected, clarified by centrifugation at 2,500xg for 10 minutes, filtered through a 0.45 μm filter, and

concentrated 10x using a 30 kDa filter (Amicon). The resulting pseudovirus was frozen at -80°C until use.

Sera

Blood samples were collected from individuals 7-30 days after receiving the second dose of either Pfizer's BNT162b2 or Moderna's mRNA-1273 COVID-19 vaccine. All study participants were enrolled in the UWARN: COVID-19 in WA study at the University of Washington. The study protocol was approved by the University of Washington Human Subjects Division Institutional Review Board (STUDY00010350).

Neutralization assays with vaccine-elicited sera and monoclonal antibodies

For neutralization assays using vaccine-elicited sera, HEK-ACE2 cells were seeded in 96-well poly-D-lysine coated plates at a density of 30,000 cells per well and grown overnight until they reached approximately 80% confluency. E406W and wildtype pseudoviruses were diluted 1:25 in DMEM and incubated with vaccine-elicited sera for 30 minutes at room temperature. Growth media was removed from the HEK-ACE2 cells and the virus-sera mixture was added to the cells. Two hours after infection, an equal volume of DMEM supplemented with 20% and 2% PenStrep was added to each well and the cells were incubated overnight. After 20-24 hours, ONE-Glo EX (Promega) was added to each well and the cells were incubated for 5 minutes at 37°C. Luminescence values were measured using a BioTek plate reader.

For neutralization assays using monoclonal antibodies, Vero-TMPRSS2 cells were seeded in 96-well plates at a density of 18,000 cells per well and grown overnight until they reached approximately 80% confluency. Neutralizations were conducted as described above with one modification: prior to the addition of the virus-antibody mixture, Vero-TMPRSS2 cells were washed 3 times with DMEM.

Luminescence readings from the neutralization assays were normalized and analyzed using GraphPad Prism 9. The relative light unit (RLU) values recorded from uninfected cells were used to define 0% infectivity and RLU values recorded from cells infected with pseudovirus without sera or antibodies were used to define 100% infectivity. ID50 and IC50 values for sera and monoclonal antibodies, respectively were determined from the normalized data points using a [inhibitor] vs. normalized response – variable slope model.

Figure S1. CryoEM processing and validation for the SARS-CoV-2 E406W spike dataset. **a-b**, Representative electron micrograph (a) and 2D class averages (b) obtained for the SARS-CoV-2 E406W spike ectodomain. Scale bar: 100 nm. (c) Gold-standard fourier shell correlation curves for the closed E406W S trimer (solid line) and locally refined E406W RBD (dashed line). **d**, Local resolution calculated using CryoSPARC for the E406W S ectodomain trimer (left, unsharpened map) and the locally refined RBD (right, sharpened map). **e**, CryoEM processing workflow.

Figure S2. Repositioning of residues 444-450 in the W406 RBD interferes sterically with cilgavimab binding. Structural superimposition of the cilgavimab (AZD1061)-bound Wuhan-Hu-1 RBD (E406, gold, PDB 7L7E) and the W406 RBD (light blue). Key reorganized regions are labeled and the steric clash is indicated by a red star.

Figure S3. The E406W mutation dampens ACE2 binding severely. a-c Biolayer interferometry binding analysis of monomeric human ACE2 to immobilized Wuhan-Hu-1 (a), Alpha (N501Y, b), or E406W (c) RBDs. d Mutation effects on avidity for dimeric human ACE2 as measured by yeast surface display¹⁷ for the E406W mutation and RBD mutations found in human-derived SARS-CoV-2 isolates deposited in GISAID as of 27 September 2021 across increasing frequency thresholds.

Figure S4. Neutralization curves for E406W/G614, shown in red, or wildtype (G164), shown in black, pseudotyped VSV using four monoclonal antibodies targeting the SARS-CoV-2 RBD. Neutralization assays were performed in triplicate and replicated twice with two batches of pseudovirus.

Figure S5. Neutralization curves against E406W/G614 S, shown in red, or wildtype (G614) S, shown in black, pseudotyped VSV for 30 sera samples collected from individuals vaccinated with either Pfizers BNT162b2 or Moderna mRNA-1273 COVID-19 vaccines. Neutralization assays were performed in triplicate and repeated at least twice with at least two distinct batches of pseudovirus.

Table S1. Cryo-EM data collection, refinement and validation statistics.

	SARS-CoV-2 S E406W Ectodomain (EMDB-xxxx) (PDB xxxx)	SARS-CoV-2 S E406W RBD (local refinement) (EMDB-xxxx) (PDB xxxx)
Data collection and processing		
Magnification	105,000	105,000
Voltage (kV)	300	300
Electron exposure (e ⁻ /Å ²)	63	63
Defocus range (µm)	0-2.6	0-2.6
Pixel size (Å)	0.843	0.843
Symmetry imposed	C3	C1
Initial particle images (no.)	950,136	1,281,585
Final particle images (no.)	427,195	113,154
Map resolution (Å)	2.3	3.4
FSC threshold	0.143	0.143
Map resolution range (Å)	2.2-8.9	2.8-9.4
Refinement		
Initial model used (PDB code)	7LXY	6M0J
Model resolution (Å)	2.4	3.5
FSC threshold	0.143	0.143
Map sharpening <i>B</i> factor (Å ²)	-72	-83

Model composition		
Non-hydrogen atoms	24,198	1,555
Protein residues	2,994	194
Ligands	54	1
<i>B</i> factors (Å ²)		
Protein	21.13	41.62
Ligand	19.14	30
R.m.s. deviations		
Bond lengths (Å)	0.014	0.013
Bond angles (°)	1.450	2.065
Validation		
MolProbity score	1.36	1.73
Clashscore	3.94	4.30
Poor rotamers (%)	0	0
Ramachandran plot		
Favored (%)	96.95	91.15
Allowed (%)	3.05	8.85
Disallowed (%)	0	0

Table S2. Binding kinetics of the RBD to human ACE2 as measured by biolayer interferometry. Values are presented as mean ± standard error.

	K_D (nM)	k_{on} (M⁻¹s⁻¹)	k_{off} (s⁻¹)
WT	93.9 ± 3.3	1.4 × 10 ⁵	1.2 × 10 ⁻²
Alpha	10.9 ± 0.9	2.3 × 10 ⁵	2.5 × 10 ⁻³
E406W	1,335 ± 195	7.6 × 10 ⁴	1.0 × 10 ⁻¹

Table S3. IC₅₀ values for the four monoclonal antibodies tested against wildtype (G164) and E406W pseudoviruses. Values are presented as mean ± standard error.

	IC₅₀ against WT pseudovirus (ng/mL)	IC₅₀ against E406W pseudovirus (ng/mL)
S309	26.6 ± 3.7	27.3 ± 2.4
S2E12	0.81 ± 0.19	0.98 ± 0.17
S2X259	39.4 ± 9.2	33.8 ± 15.6

S2H14	535 ± 224	> 20,000
--------------	-----------	----------

Table S4. Demographic information for vaccine-elicited sera donors.

Study ID	Age	Vaccine Type	Days after second vaccination	Sex	Race	Ethnicity
23	60	Pfizer	11	M	White	Not Hispanic or Latino
24	65	Pfizer	10	M	White	Not Hispanic or Latino
25	55	Pfizer	18	M	White	Not Hispanic or Latino
26	42	Pfizer	9	F	White	Not Hispanic or Latino
27	66	Moderna	8	F	White	Not Hispanic or Latino
28	63	Pfizer	10	M	White	Not Hispanic or Latino
29	27	Pfizer	8	F	White	Not Hispanic or Latino
30	38	Pfizer	8	F	Asian	Not Hispanic or Latino
31	37	Pfizer	21	F	Black	Not Hispanic or Latino
32	36	Moderna	7	M	White	Not Hispanic or Latino
33	62	Pfizer	15	M	Pacific Islander	Not Hispanic or Latino
34	54	Pfizer	14	F	White	Not Hispanic or Latino
35	60	Pfizer	14	F	White	Not Hispanic or Latino
36	32	Pfizer	13	F	White	Not Hispanic or Latino
37	52	Pfizer	11	M	White	Not Hispanic or Latino
38	61	Pfizer	9	M	White	Not Hispanic or Latino
39	32	Pfizer	22	F	White	Not Hispanic or Latino
40	40	Moderna	20	M	White	Not Hispanic or Latino
41	64	Moderna	16	M	White	Not Hispanic or Latino
42	34	Moderna	23	F	Asian	Not Hispanic or Latino
43	22	Moderna	20	F	White	Not Hispanic or Latino
44	24	Moderna	18	F	White	Not Hispanic or Latino
45	35	Moderna	20	M	White	Not Hispanic or Latino
46	40	Moderna	24	M	White	Not Hispanic or Latino
47	55	Moderna	20	M	White	Not Hispanic or Latino
48	25	Moderna	22	M	White and Asian	Not Hispanic or Latino
49	26	Moderna	18	F	White	Not Hispanic or Latino
50	36	Moderna	27	F	Asian	Not Hispanic or Latino

51	53	Moderna	20	F	White	Not Hispanic or Latino
52	47	Moderna	21	M	White	Not Hispanic or Latino

References

1. Walls, A. C. *et al.* Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell* **181**, 281–292.e6 (2020).
2. Zhou, P. *et al.* A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* (2020) doi:10.1038/s41586-020-2012-7.
3. Hoffmann, M. *et al.* SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* **181**, 271–280.e8 (2020).
4. Corti, D., Purcell, L. A., Snell, G. & Veesler, D. Tackling COVID-19 with neutralizing monoclonal antibodies. *Cell* (2021) doi:10.1016/j.cell.2021.05.005.
5. Piccoli, L. *et al.* Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. *Cell* **183**, 1024–1042.e21 (2020).
6. Greaney, A. J. *et al.* Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection. *Sci. Transl. Med.* **13**, (2021).
7. McCallum, M. *et al.* N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. *Cell* (2021) doi:10.1016/j.cell.2021.03.028.
8. Stamatatos, L. *et al.* mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. *Science* (2021) doi:10.1126/science.abg9175.
9. Starr, T. N. *et al.* Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. *Science* **371**, 850–854 (2021).

10. Starr, T. N. *et al.* SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. *Nature* (2021) doi:10.1038/s41586-021-03807-6.
11. Hansen, J. *et al.* Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. *Science* (2020) doi:10.1126/science.abd0827.
12. Baum, A. *et al.* Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. *Science* (2020) doi:10.1126/science.abd0831.
13. Dong, J. *et al.* Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. *Nat Microbiol* **6**, 1233–1244 (2021).
14. Lan, J. *et al.* Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. *Nature* (2020) doi:10.1038/s41586-020-2180-5.
15. Wrobel, A. G. *et al.* SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects. *Nat. Struct. Mol. Biol.* **27**, 763–767 (2020).
16. Park, Y.-J. *et al.* Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry. doi:10.1101/2021.10.13.464254.
17. Starr, T. N. *et al.* Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding. *Cell* **182**, 1295–1310.e20 (2020).
18. Tortorici, M. A. *et al.* Broad sarbecovirus neutralization by a human monoclonal antibody. *Nature* (2021) doi:10.1038/s41586-021-03817-4.
19. Pinto, D. *et al.* Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. *Nature* **583**, 290–295 (2020).
20. Tortorici, M. A. *et al.* Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. *Science* **370**, 950–957 (2020).
21. Jette, C. A. *et al.* Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. *Cell Rep.* **36**, 109760 (2021).

22. Martinez, D. R. *et al.* A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. *Sci. Transl. Med.* eabj7125 (2021).
23. McCallum, M. *et al.* SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. *Science* (2021) doi:10.1126/science.abi7994.
24. McCallum, M. *et al.* Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants. *Science* eabl8506 (2021).
25. Davies, N. G. *et al.* Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science* (2021) doi:10.1126/science.abg3055.
26. Tegally, H. *et al.* Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein. *Nature* (2021) doi:10.1038/s41586-021-03402-9.
27. Deng, X. *et al.* Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. *Cell* (2021) doi:10.1016/j.cell.2021.04.025.
28. Faria, N. R. *et al.* Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. *Science* **372**, 815–821 (2021).
29. Thomson, E. C. *et al.* Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. *Cell* (2021) doi:10.1016/j.cell.2021.01.037.
30. Collier, D. A. *et al.* Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. *Nature* (2021) doi:10.1038/s41586-021-03412-7.
31. Cele, S. *et al.* Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. *Nature* (2021) doi:10.1038/s41586-021-03471-w.
32. Wibmer, C. K. *et al.* SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. *Nat. Med.* (2021) doi:10.1038/s41591-021-01285-x.
33. Edara, V.-V. *et al.* Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants. *N. Engl. J. Med.* (2021) doi:10.1056/NEJMc2107799.

34. Liu, C. *et al.* Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. *Cell* (2021) doi:10.1016/j.cell.2021.06.020.
35. Plante, J. A. *et al.* Spike mutation D614G alters SARS-CoV-2 fitness. *Nature* (2020) doi:10.1038/s41586-020-2895-3.
36. Liu, Y. *et al.* Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant. *bioRxiv* (2021) doi:10.1101/2021.08.12.456173.
37. Saito, A. *et al.* Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. *Nature* (2021) doi:10.1038/s41586-021-04266-9.
38. Crawford, K. H. D. *et al.* Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays. *Viruses* **12**, (2020).
39. Hsieh, C.-L. *et al.* Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. *Science* **369**, 1501–1505 (2020).
40. Suloway, C. *et al.* Automated molecular microscopy: the new Legimon system. *J. Struct. Biol.* **151**, 41–60 (2005).
41. Tegunov, D. & Cramer, P. Real-time cryo-electron microscopy data preprocessing with Warp. *Nat. Methods* **16**, 1146–1152 (2019).
42. Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. *Nat. Methods* **14**, 290–296 (2017).
43. Punjani, A., Zhang, H. & Fleet, D. J. Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction. *Nat. Methods* **17**, 1214–1221 (2020).
44. Zivanov, J., Nakane, T. & Scheres, S. H. W. A Bayesian approach to beam-induced motion correction in cryo-EM single-particle analysis. *IUCrJ* **6**, 5–17 (2019).
45. Zivanov, J. *et al.* New tools for automated high-resolution cryo-EM structure determination in RELION-3. *Elife* **7**, (2018).

46. Scheres, S. H. W. RELION: implementation of a Bayesian approach to cryo-EM structure determination. *J. Struct. Biol.* **180**, 519–530 (2012).
47. Rosenthal, P. B. & Henderson, R. Optimal determination of particle orientation, absolute hand, and contrast loss in single-particle electron cryomicroscopy. *J. Mol. Biol.* **333**, 721–745 (2003).
48. Chen, S. *et al.* High-resolution noise substitution to measure overfitting and validate resolution in 3D structure determination by single particle electron cryomicroscopy. *Ultramicroscopy* **135**, 24–35 (2013).
49. Pettersen, E. F. *et al.* UCSF Chimera--a visualization system for exploratory research and analysis. *J. Comput. Chem.* **25**, 1605–1612 (2004).
50. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. *Acta Crystallogr. D Biol. Crystallogr.* **66**, 486–501 (2010).
51. Frenz, B. *et al.* Automatically Fixing Errors in Glycoprotein Structures with Rosetta. *Structure* **27**, 134–139.e3 (2019).
52. Wang, R. Y.-R. *et al.* Automated structure refinement of macromolecular assemblies from cryo-EM maps using Rosetta. *Elife* **5**, (2016).